Bacillus coagulans: A viable adjunct therapy for relieving symptoms of rheumatoid arthritis according to a randomized, controlled trial

David R Mandel MD Inc, Mayfield Village, OH 44143, USA.
BMC Complementary and Alternative Medicine (Impact Factor: 2.02). 01/2010; 10(1):1. DOI: 10.1186/1472-6882-10-1
Source: PubMed


Lactic acid-producing bacteria (LAB) probiotics demonstrate immunomodulating and anti-inflammatory effects and the ability to lessen the symptoms of arthritis in both animals and humans. This randomized, double-blind, placebo-controlled, parallel-design, clinical pilot trial was conducted to evaluate the effects of the LAB probiotic preparation, Bacillus coagulans GBI-30, 6086, on symptoms and measures of functional capacity in patients with rheumatoid arthritis (RA) in combination with pharmacological anti-arthritic medications.
Forty-five adult men and women with symptoms of RA were randomly assigned to receive Bacillus coagulans GBI-30, 6086 or placebo once a day in a double-blind fashion for 60 days in addition to their standard anti-arthritic medications. Arthritis activity was evaluated by clinical examination, the American College of Rheumatology (ACR) criteria, the Stanford Health Assessment Questionnaire Disability Index (HAQ-DI), and laboratory tests for erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP).
Subjects who received Bacillus coagulans GBI-30, 6086 experienced borderline statistically significant improvement in the Patient Pain Assessment score (P = .052) and statistically significant improvement in Pain Scale (P = .046) vs placebo. Compared with placebo, Bacillus coagulans GBI-30, 6086 treatment resulted in greater improvement in patient global assessment and self-assessed disability; reduction in CRP; as well as the ability to walk 2 miles, reach, and participate in daily activities. There were no treatment-related adverse events reported throughout this study.
Results of this pilot study suggest that adjunctive treatment with Bacillus coagulans GBI-30, 6086 LAB probiotic appeared to be a safe and effective for patients suffering from RA. Because of the low study population size, larger trials are needed to verify these results.

Full-text preview

Available from: PubMed Central
  • Source
    • "The clinical studies used for the analysis. Agrawal et al., 2012 Irvine et al., 2010, 2011 Ranganathan et al., 2009 Anukam et al., 2010 Ishikawa et al., 2011 Schunter et al., 2012 Bouilly-Gauthier et al., 2010 Jenks et al., 2008 Sharma et al., 2011 Chitapanarux et al., 2010 Klarin et al., 2008 Shimizu et al., 2009 Cimperman et al., 2011 Knight et al., 2009 Song et al., 2010 De los Angeles Pineda et al., 2011 Lee et al., 2010 Souza and Jorge, 2012 Diepenhorst et al., 2011 Liu et al., 2010, 2011, 2013 Stadlbauer et al., 2008 Eguchiet al., 2011 Malaguarnera et al., 2010 Steed et al., 2010 Fleming et al., 2011 Mandel et al., 2010 Stephens and Hewett, 2012 Frohmader et al., 2010 Mangell et al., 2012 Tan et al., 2011 Fujimori et al., 2009 Matthes et al., 2010 Tanaka et al., 2012 Gao et al., 2010 Mittal et al., 2011 Tandon et al., 2009 Gianotti et al., 2010 Morrow et al., 2010 Tursi et al., 2010 González-Hernández et al., 2012 Peguet-Navarro et al., 2008 Usami et al., 2011 Hemsworth et al., 2012 Peral et al., 2009 Zhang et al., 2012 Horvatet al., 2010 Pereg et al., 2011 Hummelen et al., 2010, 2011a,b Pozzoni et al., 2012 Duration "
    [Show abstract] [Hide abstract]
    ABSTRACT: This study aimed to systematically evaluate safety of probiotics and synbiotics in immune compromised adults (≥18 years). Safety was analysed using the Common Terminology Clinical Adverse Events (CTCAE version 4.0) classification, thereby providing an update on previous reports using the most recent available clinical data (2008- 2013). Safety aspects are represented and related to number of participants per probiotic strain/culture, study duration, dosage, clinical condition and selected afflictions. Analysis of 57 clinical studies indicates that probiotic and/or synbiotic administration in immune compromised adults is safe with regard to the current evaluated probiotic strains, dosages and duration. Individuals were considered immune compromised if HIV-infected, critically ill, underwent surgery or had an organ- or an autoimmune disease. There were no major safety concerns in the study, as none of the serious adverse events (AE)s were related, or suspected to be related, to the probiotic or synbiotic product and the study products were well tolerated. Overall, AEs occurred less frequent in immune compromised subjects receiving probiotics and/or synbiotics compared to the control group. In addition, the results demonstrated a flaw in precise reporting and classification of AE in most studies. Furthermore, generalisability of conclusions are greatly limited by the inconsistent, imprecise and potentially incomplete reporting as well as the variation in probiotic strains, dosages, administration regimes, study populations and reported outcomes. We argue that standardised reporting on adverse events (CTCAE) in 'food' studies should be obligatory, thereby improving reliability of data and re-enforcing the safety profile of probiotics.
    Beneficial Microbes 10/2014; 6(1):1-15. DOI:10.3920/BM2014.0079 · 2.61 Impact Factor
  • Source
    • "The anti-oxidative potential of SEA is comparable to that of Ascorbic Acid, a well-known anti-oxidant molecule. Oxidative cellular damage have shown to be primary cause of cancer [32] and anti-oxidative mechanisms have shown to reverse the oxidative damage by regulating tumor supressor genes and their products [33]. Cancer is not a single disease, it is a multifactorial disease, it can be also caused by inflammation. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Sophora interrupta belongs to the family of Fabaceae and the species in this genus have a diverse medicinal importance as a folk medicine for preventing many ailments including cancer. In order to evaluate the anticancer activity of S.interrupta, we have performed in vitro anti-oxidant, anti-inflammatory, anti-proliferative, and cell based anticancer activity in MCF-7 and PC-3 cell lines. Secondary metabolites of S.interrupta were used to identify anticancer compounds using Open Eye software. The antioxidant activity of the S.interrupta root ethylacetate (SEA) extract at 100 µg/ml is equal to that of ascorbic acid at 50 µg/ml. The antiinflammatory activity of SEA is half of that of diclofenac at 50 µg/ml. Anticancer activity was detected by measuring the mitochondrial dehydrogenase activity (MTT assay). The half maximal inhibitory concentrations (IC50) for MCF-7 and PC-3 cell lines are 250 and 700 µg/ml respectively. This was supported by the morphological changes such as membrane blebbing, cell detachment and rounded cell morphology when compared to the parental cells. In addition, we observed few green cells (live) over red cells (dead) based on the uptake of acridine orange and ethidium bromide dyes. Kaempferol-3-O-b-D-glucopyranoside, a Secondary metabolite of S.interrupta form 6 hydrogen bond interactions with Arg 202, Gln 207, Gly 227, Gly 229, Thr 231 and Ala 232 human DEAD box RNA helicase, DDX3 protein and is equivalent to crystal structure of adenosine mono phosphate to DDX3. Overall, it suggests that the SEA extract has anticancer compounds, and it can be used to enhance death receptor mediated cancer cell death.
    Bioinformation 03/2014; 10(3):144-51. DOI:10.6026/97320630010144 · 0.50 Impact Factor
    • "While the strain did prevent antibiotic-associated diarrhoea when administered with fructo-oligosaccharides, it did not have a therapeutic effect on acute watery diarrhoea in children (Dutta et al., 2011; La Rosa et al., 2003). In a small population study, B. coagulans GanedenBC 30 administered together with standard anti-arthritic medication relieved symptoms of rheumatoid arthritis (Mandel et al., 2010). A number of products for human use are being marketed in Europe, Asia and the USA. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit to the host. The two main genera of microorganisms indicated as sources of probiotic bacteria are Lactobacillus and Bifidobacterium. Historically used to produce fermented dairy products, certain strains of both genera are increasingly utilised to formulate other functional foods. As the consumers' understanding of the role of probiotics in health grows, so does the popularity of food containing them. The result of this phenomenon is an increase in the number of probiotic foods available for public consumption, including a rapidly-emerging variety of probiotic-containing non-dairy beverages, which provide a convenient way to improve and maintain health. However, the composition of non-dairy probiotic beverages can pose specific challenges to the survival of the health conferring microorganisms. To overcome these challenges, strain selection and protection techniques play an integral part in formulating a stable product. This review discusses non-dairy probiotic beverages, characteristics of an optimal beverage, and commonly used probiotic strains, including spore-forming bacteria. It also examines the most recent developments in probiotic encapsulation technology with focus on nano-fibre formation as a means of protecting viable cells. Utilising bacteria's natural armour or creating barrier mechanisms via encapsulation technology will fuel development of stable non-dairy probiotic beverages.
    Beneficial Microbes 12/2012; 4(2):1-16. DOI:10.3920/BM2012.0030 · 2.61 Impact Factor
Show more